Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2L-KLH + GD3L-KLH
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral
01
Overview
GD2L-KLH + GD3L-KLH is a bivalent conjugate cancer vaccine developed by Memorial Sloan Kettering Cancer Center for the treatment of high-risk neuroblastoma. The vaccine consists of two ganglioside antigens, GD2 lactone (GD2L) and GD3 lactone (GD3L), each individually conjugated to the immunological carrier protein keyhole limpet hemocyanin (KLH). It is designed to induce a humoral immune response (antibodies) against GD2 and GD3, which are highly expressed on the surface of neuroblastoma cells. The vaccine is typically administered subcutaneously in combination with the saponin-based adjuvant OPT-821 and oral beta-glucan to enhance the immune system's ability to identify and destroy residual cancer cells.
- Other names
- Bivalent GD2L/GD3L vaccineGD2L-KLH/GD3L-KLH vaccineGD2L-KLH and GD3L-KLH vaccineGD-2L-KLH and GD3L-KLH vaccineGD 2L-KLH and GD3L-KLH vaccine
02
Targets
GD2GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on GD2L-KLH + GD3L-KLH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2L-KLH + GD3L-KLH.